FY2025 · ended Dec 31, 2025 · Revenue $36,000, -41.0% YoY · Filed Mar 12, 2026
Lyell Immunopharma, Inc. (LYEL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $36,000 and a net loss of $274.4 million. Free cash flow was -$150.8 million. As of Sep 30, 2026 it held $194.0 million in cash and investments and $44.3 million in total debt.
Revenue (TTM)
$15,000
-63.4% vs year-ago TTM
Net income (TTM)
$-255.16M
+21.6% vs year-ago TTM
Operating cash flow (TTM)
$-139.25M
+15.6% vs year-ago TTM
Free cash flow (TTM)
$-139.97M
+15.4% vs year-ago TTM
EPS (TTM)
$-11.32
+46.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
23.31M
-92.1% vs prior year
Net cash
$149.70M
as of Sep 30, 2026
Operating margin
-1783580.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LYEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806952
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M |
| Diluted EPS | -$16.06 | -$26.23 | -$18.70 | -$0.74 | -$1.84 |
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.1B |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
| Stockholders' equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M |
| Cash and investments | $247.2M | $383.5M | $562.7M | $710.3M | $898.3M |
| Total debt | $51.0M | $59.0M | $63.2M | $67.7M | $67.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Nov 4, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 359 Lyell Immunopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.